AS601245 (1,3-benzothiazol-2-yl(2-{[2-(3-pyridinyl)ethyl]amino}-4 pyrimidinyl) acetonitrile):: A c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties

AS601245 (1,3-benzothiazol-2-yl(2-{[2-(3-pyridinyl)ethyl]amino}-4 pyrimidinyl) acetonitrile):: A c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties
复制标题

DOI:
10.1124/jpet.103.064246
复制
发表时间:
2004-07-01
影响因子:
3.5
通讯作者:
Vitte, PA
Vitte, PA
中科院分区:
医学2区
文献类型:
--
作者:
Carboni, S;Hiver, A;Vitte, PA

文献摘要

被引文献

相似文献

最近的证据表明,c-Jun氨基末端蛋白激酶(JNK)信号转导通路的激活可能在缺血诱导的细胞死亡中发挥作用。因此,防止JNK或c-Jun磷酸化的激活可能具有神经保护作用。在目前的研究中,我们报告了一种小分子,AS 601245(1,3-苯并噻唑-2-基(2-{[2-(3-吡啶基)乙基]氨基}-4嘧啶基)乙腈),它已被证明可以抑制JNK信号通路,促进脑缺血后的细胞存活。在体内,在短暂性全脑缺血的沙鼠模型中,腹腔注射AS 601245(40、60和80 mg/kg)可显著保护海马CA 1区神经元的延迟性丢失。这种作用是由JNK抑制介导的,因此是由c-Jun表达和磷酸化介导的。在大鼠局灶性脑缺血后,还观察到AS 601245通过i. p.注射(6、18和60 mg/kg)或i. v.推注(1 mg/kg)后i. v.输注(0.6 mg/kg/h)给药的显著神经保护作用。这些数据表明,使用JNK抑制剂如AS 601245可能是治疗缺血性损伤的相关策略。
Recent evidence suggests that activation of the c-Jun NH2-terminal protein kinase (JNK) signal transduction pathway may play a role in ischemia-induced cell death. Thus, preventing the activation of JNK, or c-Jun phosphorylation could be neuroprotective. In the current study, we report that a small molecule, AS601245 (1,3-benzothiazol-2-yl (2-{[2-(3-pyridinyl) ethyl] amino}-4 pyrimidinyl) acetonitrile), which has been shown to inhibit the JNK signaling pathway, promotes cell survival after cerebral ischemia. In vivo, AS601245 (40, 60, and 80 mg/kg) administered i.p. provided significant protection against the delayed loss of hippocampal CA1 neurons in a gerbil model of transient global ischemia. This effect is mediated by JNK inhibition and therefore by c-Jun expression and phosphorylation. A significant neuroprotective effect of AS601245 administered either by i.p. injection (6, 18, and 60 mg/kg) or as i.v. bolus (1 mg/kg) followed by an i.v. infusion (0.6 mg/kg/h) was also observed in rats after focal cerebral ischemia. These data suggest that the use of JNK inhibitors such as AS601245 may be a relevant strategy in the therapy of ischemic insults.